Data on new Novo Nordisk obesity drug disappoints in trial, shares drop
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...
Yahoo Finance8d
'For Novo Nordisk, I do not worry a lot about tariffs:' CEO Lars Jørgensen
The states they will be located in are not yet known. FILE PHOTO: The logo of Danish drugmaker Novo Nordisk in their offices in Hillerod, Denmark, September 26, 2023. REUTERS/Tom Little/File Photo ...
The Australian Financial Review5d
Ozempic maker says its Australian market could be half the population
Novo Nordisk executive Camilla Sylvest says Australia generally has a relatively high prevalence of obesity compared with many other countries. Asked about the potential size of the Australian ...
Business Insider6d
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
New York, New York--(Newsfile Corp. - March 8, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between November 2 ...
Fierce Pharma7d
With blood and growth disorder bids panning out, Novo Nordisk plots path to rare disease leadership: exec
Still, Novo is steadfast in its goal to eventually become a leader in the space, the company’s EVP of rare disease, Ludovic ...
Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped
Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...
The Washington Post9d
Novo Nordisk slashes Wegovy price for patients lacking insurance benefits
Novo Nordisk said Wednesday it will sell Wegovy for $499 a month in cash to patients who can’t get the blockbuster weight-loss drug through insurance, a bid to reach consumers who can’t afford ...
Euronews8d
Novo Nordisk shares jump after Wegovy price cuts announced
Europe’s largest pharmaceutical firm, Novo Nordisk, has announced that it will offer its most popular weight-loss drug, Wegovy, for less than half of its listed price. This follows a similar ...
Business Insider28d
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE:NVO) between November 2, 2022 and December 19, 2024, both dates inclusive (the ...
The Motley Fool9d
Down 39%. Is Novo Nordisk Stock a Buy on the Dip?
Novo Nordisk stock has fallen roughly 40% from a peak it reached last June. The U.S. Food and Drug Administration recently confirmed Novo Nordisk is producing enough Ozempic and Wegovy to meet demand.
AOL8d
'For Novo Nordisk, I do not worry a lot about tariffs:' CEO Lars Jørgensen
Novo Nordisk (NVO) is not concerned by the ongoing US trade war and the 25% tariff set to go into effect for pharmaceutical companies next week. CEO Lars Jørgensen told reporters Thursday ...
Ibj.com9d
Novo Nordisk cuts Wegovy prices, following similar move for Zepbound by Eli Lilly
Novo Nordisk said Wednesday it will sell Wegovy for $499 a month in cash to patients who can’t get the blockbuster weight-loss drug through insurance, a bid to reach consumers who can’t afford ...